



Marinus Pharmaceuticals
Investor Relations Department
170 N. Radnor Chester Road,
Suite 250
Radnor, PA 19087-5279
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: MRNS

| | |
|---------------|---|
| Last Trade: | 1.81 |
| Trade Time: | 4:00 PM ET Jul 24, 2017 |
| Change: | 0.10 ▲ (+5.848%) |
| Day Range | 1.70 - 1.82 |
| 52-Week Range | 0.82 - 2.73 |
| Volume | 521,863 |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 29, 2017

[FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder](#)

Jun 27, 2017

[Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression](#)

May 1, 2017

[Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results](#)

Apr 18, 2017

[Marinus to present Ganaxolone DATA at American academy of neurology annual meeting](#)

Apr 11, 2017

[Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer](#)

Upcoming Events [\[View all \]](#)

Sep 6, 2017

[International Epilepsy Congress](#)

Financials & Filings [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Mar 16, 2017

[Proxy Statement \(DEF 14A\)](#)

May 1, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)

Aug 9, 2016

[Quarterly Report \(10-Q\)](#)